Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Aluwini S, et al. Among authors: van der toorn pp. Lancet Oncol. 2016 Apr;17(4):464-474. doi: 10.1016/S1470-2045(15)00567-7. Epub 2016 Mar 9. Lancet Oncol. 2016. PMID: 26968359 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F. Incrocci L, et al. Among authors: van der toorn pp. Lancet Oncol. 2016 Aug;17(8):1061-1069. doi: 10.1016/S1470-2045(16)30070-5. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339116 Clinical Trial.
Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Among authors: van lin e, van der toorn pp. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.
Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume.
Borger JH, Hooning MJ, Boersma LJ, Snijders-Keilholz A, Aleman BM, Lintzen E, van Brussel S, van der Toorn PP, Alwhouhayb M, van Leeuwen FE. Borger JH, et al. Among authors: van der toorn pp, van brussel s, van leeuwen fe. Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1131-8. doi: 10.1016/j.ijrobp.2007.04.042. Epub 2007 Jul 2. Int J Radiat Oncol Biol Phys. 2007. PMID: 17606332
What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using model-based deformable image registration techniques.
Meijer GJ, de Klerk J, Bzdusek K, van den Berg HA, Janssen R, Kaus MR, Rodrigus P, van der Toorn PP. Meijer GJ, et al. Among authors: van der toorn pp, van den berg ha. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1416-25. doi: 10.1016/j.ijrobp.2008.03.005. Epub 2008 Apr 24. Int J Radiat Oncol Biol Phys. 2008. PMID: 18439767
23 results